Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00735267 · ClinicalTrials.gov registry record · Phase 3
A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder (GAD)
A Phase 3 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 468
- Enrollment target
NCT00735267 is a Phase 3 study that was terminated before completion, run by Pfizer. The registered enrollment target is 468 participants.
The verdict
NCT00735267, a Phase 3 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 468 participants
- Enrollment target
Study Summary
This study will assess the long-term safety and tolerability of 350 to 600 mg/day of PD 0332334 administered in split dose (twice daily) in subjects with Generalized Anxiety Disorder.
Interventions
- DRUG PD 0332334
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 468 participants |
| Start Date | 2008-10 |
| Est. Completion | 2009-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00735267
The ClinicalTrials.gov registry entry for NCT00735267 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 468 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PD 0332334 is the first listed.
NCT00735267 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00735267 about?
NCT00735267 is a clinical study titled "A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder (GAD)". This study will assess the long-term safety and tolerability of 350 to 600 mg/day of PD 0332334 administered in split dose (twice daily) in subjects with Generalized Anxiety Disorder.
What is the current status of trial NCT00735267?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 468 participants. The study started on 2008-10. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00735267?
The interventions under investigation include: PD 0332334 (DRUG).
Who is sponsoring clinical trial NCT00735267?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.